ArticleCancer cell2020
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Application and prospect of organoid technology in breast cancer.Frontiers in immunology · 2024Pooled it
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Integrative Transcriptional and Chromatin Analyses Reveal Enhancer-Mediated Regulatory Programs Driving Breast Cancer Metastasis.Molecular cancer research : MCR · 2026Article
- FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.Histopathology · 2026Article
- Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.Pharmaceuticals (Basel, Switzerland) · 2026Article
- CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.British journal of cancer · 2026Article
- Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.bioRxiv : the preprint server for biology · 2026Article
- FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.Cell reports · 2026Article
- BRD4-associated chromatin remodelling signature links epigenetic regulation to immune landscape in ovarian cancer.Journal of ovarian research · 2026Article
- The Complex Path from Mammary Ductal Hyperplasia to Breast Cancer: Elevated Malignancy Risk in Atypical Forms.Biomedicines · 2026Review
- Review
- CoFormerSurv: Collaborative transformer for multi-omics survival analysis.PLoS computational biology · 2026Article
- Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2.Molecular cancer research : MCR · 2025Article
- OT17 a novel microsatellite stable colorectal cancer cell line and organoid model for investigatingBiochemistry and biophysics reports · 2025Article
- The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding.Nucleic acids research · 2025Article
- Chromatin Regulatory Targets for Anticancer Therapeutics.Chemical reviews · 2025Review
- The Role of Non-Coding Regions in Breast Cancer: From Gene Regulation to Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states.Nature communications · 2025Article
- Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer.Cell reports. Medicine · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 4 countries.
Amaia Arruabarrena-AristorenaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jesper L V MaagCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Srushti KittaneHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yanyan CaiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wouter R KarthausHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Erik LadewigHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jane ParkCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Srinivasaraghavan KannanBioinformatics Institute (A(∗)STAR), 30 Biopolis Street, 07-01 Matrix, Singapore 138671, Singapore.
Lorenzo FerrandoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Internal Medicine, University of Genoa, Genova, Italy.
Emiliano CoccoHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sik Y HoSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Daisylyn S TanSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Mirna SallakuHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Fan WuHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Barbara AcevedoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Dara S RossDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Matthew WitkinCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Charles L SawyersHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chandra S VermaBioinformatics Institute (A(∗)STAR), 30 Biopolis Street, 07-01 Matrix, Singapore 138671, Singapore; Department of Biological Sciences, National University of Singapore, 14 Science Drive, Singapore 117543, Singapore; School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.
Ralf JauchSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
José BaselgaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Research & Development Oncology, AstraZeneca Pharmaceuticals, Gaithersburg, MD 20878, USA.
Pedram RazaviHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eneda ToskaHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: etoska1@jhmi.edu.
Maurizio ScaltritiHuman Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: scaltrim@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of Hong Kong · HKAgency for Science, Technology and Research · SG
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUnraveling resistance to PI3K-alpha inhibitors in breast cancerR01CA190642 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCALTRITI, MAURIZIO · 2015 to 2019
$2.2MResistance and Evolution of Metastatic Breast CancerK00CA212478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADEWIG, ERIK · 2018 to 2021
$369kNCI NIH HHS K00 CA212478NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA190642
Abstract
Mutations in the pioneer transcription factor FOXA1 are a hallmark of estrogen receptor-positive (ER
Indexed as
Mutation, MissenseAnimalsAromatase InhibitorsBreast NeoplasmsCell Line, TumorChromatinEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansMCF-7 CellsMice, NudeModels, MolecularProtein DomainsAromatase InhibitorsChromatinEstrogen Receptor alphaFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphabreast cancerchromatin accessibilityendocrine therapyepigenomicsESR1 mutationsestrogen receptorFOXA1 mutationspioneer transcription factortranscriptiontranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.